Form 4: Voyager Therapeutics COO Sells Shares for Tax Obligations

Voyager Therapeutics' COO & CBO, Robin Swartz, sold 4,569 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Robin Swartz, Chief Operating Officer and Chief Business Officer of Voyager Therapeutics, Inc. (VYGR), reported a sale of common stock.
• The transaction involved the disposition of 4,569 shares of common stock on February 10, 2026.
• The shares were sold at a weighted average price of $3.85 per share, with individual transaction prices ranging from $3.72 to $3.90.
• This sale was not a discretionary trade by the reporting person but was executed pursuant to a durable automatic sales instruction letter to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) on February 9, 2026.
• Following this transaction, Robin Swartz beneficially owns 210,078 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is explicitly stated as non-discretionary and for tax purposes, which is a routine administrative action for executives receiving equity compensation, rather than a reflection of management's outlook on the company's performance.

Future Outlook

NA

Management Comments

• The sale of common stock represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The sales do not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions, where executives sell a portion of their vested equity awards to cover tax liabilities, are a common and routine occurrence in the biotechnology and broader corporate sectors. These transactions are typically non-discretionary and are not usually indicative of an executive's sentiment regarding the company's future prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and not a strategic divestment by an insider.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell-to-cover' transaction by an executive to satisfy tax obligations related to RSU vesting. Such transactions are common and generally do not reflect a change in the executive's confidence in the company's future or warrant a shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new fundamental information to alter an existing investment thesis.

Keywords

Voyager Therapeutics, VYGR, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Tax Withholding, Robin Swartz